VIVUS (NASDAQ:VVUS) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.24, Fidelity Earnings reports. The company had revenue of $18.09 million for the quarter.
Shares of NASDAQ VVUS traded up $0.67 on Friday, hitting $4.08. The company’s stock had a trading volume of 353,290 shares, compared to its average volume of 90,335. VIVUS has a 12-month low of $3.30 and a 12-month high of $9.90. The company has a market capitalization of $37.92 million, a PE ratio of -1.41 and a beta of 0.58.
Several research analysts have weighed in on the stock. ValuEngine upgraded shares of VIVUS from a “hold” rating to a “buy” rating in a research report on Thursday. Zacks Investment Research upgraded shares of VIVUS from a “sell” rating to a “hold” rating in a research report on Monday, October 8th.
VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Further Reading: What is a Market Correction?
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.